Skip to main content
TipRanks
Go Ultimate75% OFF

Knight Therapeutics (KHTRF) Q3 2026 Earnings Report

33 Followers

KHTRF Q3 2026 EPS Results

Actual EPS
-$0.02
Consensus EPS
$0.01
Beat/Miss
Missed by -$0.03
One Year Ago EPS
-$0.03

KHTRF Q3 2026 Revenue Results

Actual Revenue
$97.04M
Expected Revenue
$91.05M
Beat/Miss
Beat by +$5.98M
YoY Revenue Growth
+13.28%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
KHTRF Upcoming Earnings

Knight Therapeutics's next earnings date is estimated for March 25, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

KHTRF Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:3.21%|
Earnings Call Sentiment|Positive

The call was strongly positive, supported by record nine-month results, double-digit quarterly growth, raised revenue and adjusted EBITDA guidance, expanded peak revenue potential, strong cash generation, successful product launches, and continued business development momentum. The main challenges were expected pressure on AmBisome from generic competition beginning in 2027, a decline in the promoted strategic portfolio, higher operating expenses, and pending regulatory work for certain products. Management nevertheless characterized current product performance, margins, and the longer-term outlook favorably.

Company Guidance

For fiscal 2026, Knight expects revenues between $560 million and $570 million, representing top line growth of at least 24% versus 2025, and adjusted EBITDA to be approximately 17.5% of revenues, representing EBITDA growth of at least 34% versus 2025; this guidance assumes there is no material adjustment due to hyperinflation accounting in Argentina. Knight increased peak revenue potential for its pipeline and launch pipeline products from over $200 million to over $300 million, covering more than 75 product launches, 22 of which have already been executed, with peak annual revenues expected closer to 4 to 5 years; launch pipeline products generated over $67 million in revenues over the last 12 months, or more than 22% of the new peak revenue estimate. The company expects EBITDA margins to remain consistent over the next couple years, with EBITDA margins to start accelerating two to three years out, and expects to have a really high EBITDA to cash flow conversion, although there could be lumpiness between quarters.

  • Record Nine-Month Revenue and Adjusted EBITDAKnight reported record results for the first nine months of 2026, with revenue of $430 million and adjusted EBITDA of over $76 million, representing growth of 36% and 57%, respectively, compared with the same period last year. Nine-month adjusted EBITDA exceeded the adjusted EBITDA reported for all of 2025.
  • Strong Third-Quarter Financial PerformanceThird-quarter revenue was $138 million, an increase of $16 million or 13% year over year, while adjusted EBITDA was $24 million, up $3 million or 13%. On a constant currency basis, revenue increased by $5 million or 4%. Adjusted EBITDA per share increased 15% to $0.24.
  • Promoted and Launch Pipeline GrowthCommercial execution drove 39% growth in the promoted portfolio for the first nine months. In the third quarter, promoted products grew 10%, while launch pipeline products generated $21 million of revenue, up $12 million or 137% on a constant currency basis, driven by launches including Orgovyx, Imvexxy, Xcopri, Myfembree, Jornay PM, and Minjuvi.
  • Improved Gross MarginThird-quarter adjusted gross margin increased to $70 million, or 51% of revenue, compared with $60 million, or 49% of revenue, in the same period last year. The increase in gross margin percentage was driven by product mix.
  • Raised Fiscal 2026 GuidanceKnight raised its fiscal 2026 outlook to revenue of $560 million to $570 million, representing top-line growth of at least 24% versus 2025. Adjusted EBITDA is expected to be approximately 17.5% of revenue, representing EBITDA growth of at least 34% versus 2025. The increase was driven primarily by stronger promoted-product performance across multiple countries and LATAM currencies performing better against the Canadian dollar than previously anticipated.
  • Expanded Pipeline and Launch Pipeline PotentialKnight increased the peak revenue outlook for its pipeline and launch pipeline products from over $200 million to over $300 million. The company said the majority of the $300 million potential comes from products that are already approved, with the increase driven by strong product performance, additional products added by the business development team, and execution by regulatory, quality, medical, and commercial teams.
  • Broad Product Launch ExecutionThe pipeline now covers more than 75 product launches across Canada and Latin America, with 22 launches executed since January 2024. Since the beginning of the third quarter, Knight launched Wynzora in Canada, Tavalisse in Brazil, Durivast in Colombia and Peru, and Minjuvi for follicular lymphoma in Mexico.
  • Regulatory Approvals and SubmissionsKnight submitted Gemtesa for regulatory approval in Canada and Minjuvi for first-line diffuse large B-cell lymphoma in Brazil. It also obtained approval for Tavalisse in Colombia, Niktimvo in Brazil, and Minjuvi for follicular lymphoma in Mexico.
  • Poteligeo Distribution AgreementKnight signed an exclusive distribution agreement with Kyowa Kirin International to commercialize Poteligeo in certain Latin American countries. Poteligeo is approved in the United States and Europe for adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy, and Knight plans to submit it for approval in LATAM over the coming months.
  • Poteligeo Clinical and Commercial FitManagement said Poteligeo demonstrated significantly longer progression-free survival and a higher overall response rate than vorinostat in the MAVORIC study. The product addresses high unmet need, fits Knight's established hemato-oncology commercial infrastructure, and generated approximately USD 200 million in U.S. sales over the last 12 months.
  • Strong Performance of Canadian Launch ProductsManagement said Orgovyx, Xcopri, Myfembree, and Imvexxy are performing ahead of expectations. The uptake curve for Orgovyx and Xcopri was faster than originally expected, Orgovyx and Myfembree expanded physician reach, and Imvexxy was exceeding expectations across all provinces.
  • Strong Cash Generation and Balance SheetKnight generated $96 million of operating cash flow in the first nine months of 2026. It ended the quarter with $137 million in cash and marketable securities and a net cash position of $115 million, compared with a net debt position one year earlier. The company also has $140 million of committed credit capacity and an additional $140 million available through the accordion feature.
  • High EBITDA-to-Cash-Flow ConversionManagement attributed the improvement in cash flow to EBITDA growth, a diversified portfolio and geography mix, faster collections from the larger Canadian business, and operating at a normal level of working capital in 2026. The company expects high EBITDA-to-cash-flow conversion going forward, although quarterly results may remain lumpy.
  • Business Development Capacity and Partner PositionKnight said it continues to see many opportunities in its markets and will continue pursuing growth assets, new launches, and acquisitions or licensing transactions involving products or portfolios with existing sales. Management said its balance sheet and access to cash and credit impose no restrictions on this activity and that Knight is becoming a partner of choice through relationships including Incyte.
  • Share Repurchase Program CompletedKnight completed the normal course issuer bid launched in August 2025, purchasing nearly 2 million common shares at an average price of $6.21 for aggregate cash consideration of $12 million.
  • Long-Term Margin Expansion OpportunityManagement said newer license agreements have better gross-margin contributions than older inherited agreements. Although margins are expected to remain at current levels for the next couple of years while Knight continues investing in pipeline and promoted assets, EBITDA margin expansion is expected as those products contribute more to the bottom line.
  • Near-Term Peak Revenue TimingManagement expects the pipeline and launch pipeline products to approach peak revenue toward the lower end of the discussed range, with products launched in 2024 and 2025 expected to reach peak levels in approximately four to five years.
  • Canadian Business Surpassed Historical BenchmarkKnight said its Canadian business has already surpassed the $145 million in revenue generated by Paladin Labs' Canadian business in 2013, and continues to grow. The company expects 2026 revenue of $560 million to $570 million and adjusted EBITDA of nearly $100 million.

KHTRF Earnings History

KHTRF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 25, 20272026 (Q4)0.04-0.06――
Nov 05, 20262026 (Q3)0.01-0.02-0.0325.00% (+0.01)
Aug 06, 20262026 (Q2)0.01-0.02-0.0976.92% (+0.07)
May 07, 20262026 (Q1)0.020.090.01550.00% (+0.08)
Mar 19, 20262025 (Q4)-0.000.060.08-18.18% (-0.01)
Nov 06, 20252025 (Q3)-0.00-0.030―
Aug 07, 20252025 (Q2)0.01-0.09-0.01-550.00% (-0.08)
May 08, 20252025 (Q1)0.000.01-0.03150.00% (+0.04)
Mar 20, 20252024 (Q4)0.010.08-0.16147.83% (+0.24)
Nov 07, 20242024 (Q3)0.010.000.06-100.00% (-0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed